These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27142718)

  • 1. Development of a Human Whole Blood Screening Platform to Monitor JAK/STAT Signaling Using High-Throughput Flow Cytometry.
    Fereshteh MP; Li X; Li S; Fan Y; Zhang R; Farr GA; Kolodin G; Lippy J; Naglich JG; Schieven G; Schweizer L; Zhang L
    J Biomol Screen; 2016 Sep; 21(8):866-74. PubMed ID: 27142718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automation of a phospho-STAT5 staining procedure for flow cytometry for application in drug discovery.
    Malergue F; van Agthoven A; Scifo C; Egan D; Strous GJ
    J Biomol Screen; 2015 Mar; 20(3):416-21. PubMed ID: 25325258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.
    Vafadari R; Weimar W; Baan CC
    Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
    Venugopal S; Bar-Natan M; Mascarenhas JO
    Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of JAK/STAT signaling pathway prevents high-glucose-induced increase in endothelin-1 synthesis in human endothelial cells.
    Manea SA; Manea A; Heltianu C
    Cell Tissue Res; 2010 Apr; 340(1):71-9. PubMed ID: 20217138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
    Welsch K; Holstein J; Laurence A; Ghoreschi K
    Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.
    Groner B; von Manstein V
    Mol Cell Endocrinol; 2017 Aug; 451():1-14. PubMed ID: 28576744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway.
    Seo SK; Seo DI; Park WS; Jung WK; Lee DS; Park SG; Choi JS; Kang MS; Choi YH; Choi I; Yu BC; Choi IW
    Life Sci; 2014 Sep; 112(1-2):82-9. PubMed ID: 25072357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
    Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
    Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
    Cornez I; Yajnanarayana SP; Wolf AM; Wolf D
    Mol Cell Endocrinol; 2017 Aug; 451():88-96. PubMed ID: 28131742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma.
    Vale K
    Future Med Chem; 2016; 8(4):405-19. PubMed ID: 26934038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.
    Vaddi K; Luchi M
    Expert Opin Investig Drugs; 2012 Jul; 21(7):961-73. PubMed ID: 22612502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of NF-kB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics.
    Ivanenkov YA; Balakin KV; Lavrovsky Y
    Mini Rev Med Chem; 2011 Jan; 11(1):55-78. PubMed ID: 21034406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
    Xu P; Shen P; Yu B; Xu X; Ge R; Cheng X; Chen Q; Bian J; Li Z; Wang J
    Eur J Med Chem; 2020 Apr; 192():112155. PubMed ID: 32120325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
    Flamant M; Rigaill J; Paul S; Roblin X
    Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An insight into JAK-STAT signalling in dermatology.
    Palanivel JA; Macbeth AE; Chetty NC; Levell NJ
    Clin Exp Dermatol; 2014 Jun; 39(4):513-8. PubMed ID: 24825142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of methotrexate as a heterochromatin-promoting drug.
    Loyola AC; Zhang L; Shang R; Dutta P; Li J; Li WX
    Sci Rep; 2019 Aug; 9(1):11673. PubMed ID: 31406262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.